The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro.

Safaeian L, Vaseghi G, Mirian M, Firoozabadi MD

Research in pharmaceutical sciences28 Aug 2020Cited by 3 (Europe PMC)

PMID33312210PMCIDPMC7714014DOI10.4103/1735-5362.293510PepBankPUB-33312210

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In HUVECs, pramlintide did not inhibit proliferation.
In plain wordsIn cells, pramlintide did not inhibit endothelial cell growth.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeCell proliferation
Study
humann: not reported in source
Human umbilical vein endothelial cells
Outcome group
Cell proliferation and differentiation · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Pramlintide exhibited no inhibitory effect on HUVECs proliferation.
1 context sentence(design, population, supporting numbers)
Summary · context
The present investigation aimed at surveying the effect of pramlintide on angiogenesis-related markers in human umbilical vein endothelial cells (HUVECs).
Report a problemFND-3331221001
02LabIn vitro (cells)Activity measurement
In HUVECs, pramlintide significantly increased cell migration.
In plain wordsIn cells, pramlintide increased endothelial cell movement.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseCell migration
Study
humann: not reported in source
Human umbilical vein endothelial cells
Outcome group
Angiogenesis · Cardiovascular
Studied dose
1 μg/mLAs given in this study (human).
Source sentences
Summary
It significantly increased cell migration at the concentration of 1 μg/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
The present investigation aimed at surveying the effect of pramlintide on angiogenesis-related markers in human umbilical vein endothelial cells (HUVECs).
Report a problemFND-3331221002
03LabIn vitro (cells)Activity measurement
In HUVECs, pramlintide increased average tubule length.
In plain wordsIn cells, pramlintide increased the average length of vessel-like tubes.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseAverage tubule length
Study
humann: not reported in source
Human umbilical vein endothelial cells
Outcome group
Angiogenesis · Cardiovascular
Studied dose
1 μg/mLAs given in this study (human).
Source sentences
Summary
Pramlintide (1 μg/mL) also enhanced average tubules length, size, and the mean number of junctions.
1 context sentence(design, population, supporting numbers)
Summary · context
The present investigation aimed at surveying the effect of pramlintide on angiogenesis-related markers in human umbilical vein endothelial cells (HUVECs).
Report a problemFND-3331221003
04LabIn vitro (cells)Activity measurement
In HUVECs, pramlintide increased tubule size.
In plain wordsIn cells, pramlintide increased the size of vessel-like tubes.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseTubule size
Study
humann: not reported in source
Human umbilical vein endothelial cells
Outcome group
Angiogenesis · Cardiovascular
Studied dose
1 μg/mLAs given in this study (human).
Source sentences
Summary
Pramlintide (1 μg/mL) also enhanced average tubules length, size, and the mean number of junctions.
1 context sentence(design, population, supporting numbers)
Summary · context
The present investigation aimed at surveying the effect of pramlintide on angiogenesis-related markers in human umbilical vein endothelial cells (HUVECs).
Report a problemFND-3331221004
05LabIn vitro (cells)Activity measurement
In HUVECs, pramlintide increased the mean number of junctions.
In plain wordsIn cells, pramlintide increased the mean number of junctions in vessel-like tubes.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseMean junction number
Study
humann: not reported in source
Human umbilical vein endothelial cells
Outcome group
Angiogenesis · Cardiovascular
Studied dose
1 μg/mLAs given in this study (human).
Source sentences
Summary
Pramlintide (1 μg/mL) also enhanced average tubules length, size, and the mean number of junctions.
1 context sentence(design, population, supporting numbers)
Summary · context
The present investigation aimed at surveying the effect of pramlintide on angiogenesis-related markers in human umbilical vein endothelial cells (HUVECs).
Report a problemFND-3331221005
06LabIn vitro (cells)Activity measurement
In HUVECs, pramlintide did not significantly change VEGF release.
In plain wordsIn cells, pramlintide did not significantly change VEGF release.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeVEGF release
Study
humann: not reported in source
Human umbilical vein endothelial cells
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
However, there was not any significant change in VEGF release from HUVECs.
1 context sentence(design, population, supporting numbers)
Summary · context
The present investigation aimed at surveying the effect of pramlintide on angiogenesis-related markers in human umbilical vein endothelial cells (HUVECs).
Report a problemFND-3331221006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.